Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | CCR1 | P32246 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | CCR8 | P51685 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740308 | 1.00 | LMNA (0.50) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL29740307 | 0.98 | LMNA (0.48) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL7325665 | 0.80 | ALDH1A1 (0.44) | MAPTKDM4ETDP1NUDT1TYMS | |
| SCHEMBL31064745 | 0.79 | MAPT (0.55) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL9803225 | 0.79 | MAPT (0.55) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL8544920 | 0.79 | LMNA (0.50) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL9803452 | 0.79 | MAPT (0.46) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL1490778 | 0.78 | NUDT1 (0.42) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL10656134 | 0.78 | MAPT (0.48) | LMNAMAPTKDM4ETSHRTP53 | |
| SCHEMBL3822260 | 0.76 | CA1 (0.50) | LMNAMAPTKDM4ETSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| EP-4648801-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4648800-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | claimed |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-10 | — | — | US | claimed |
| WO-2024151890-A9 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | claimed |
| WO-2024149345-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | claimed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | claimed |
| WO-2003094836-A2 | METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-11-20 | — | — | WO | claimed |
| US-20030190308-A1 | Adjuvant | BRAUN RALPH P (US) | 2003-10-09 | — | — | US | claimed |
| US-20030185835-A1 | Adjuvant for vaccines | POWDERJECT RESEARCH LIMITED (GB) | 2003-10-02 | — | — | US | claimed |
| WO-2003080114-A2 | IMIDAZOQUINOLINE ADJUVANTS FOR VACCINES | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080112-A2 | IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003072026-A2 | METHOD OF REDUCING AND TREATING UVB-INDUCED IMMUNOSUPPRESSION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030161797-A1 | Method of reducing and treating UVB-induced immunosuppression | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | claimed |
| US-20030139364-A1 | Methods and products for enhancing immune responses using imidazoquinoline compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2003-07-24 | — | — | US | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
| US-6486168-B1 | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | LMNA 1233/4885MAPT 2416/4885KDM4E 3970/4885 |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PTK2B, PTK2, LTK | LMNA 4448/4885MAPT 3765/4885KDM4E 2816/4885 |
| US-20030190308-A1 | Adjuvant | TLR9, TLR3, TLR5 | LMNA 3172/4885MAPT 2002/4885KDM4E 4173/4885 |
| US-20030185835-A1 | Adjuvant for vaccines | TLR9, TLR3, TLR5 | LMNA 2386/4885MAPT 3170/4885KDM4E 4456/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | LMNA 775/4885MAPT 1457/4885KDM4E 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.